# Kenneth J. O’Byrne

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kenneth-j-o-byrne/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,656 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 91 |
| i10-index | 371 |
| Last Known Institution | Princess Alexandra Hospital |
| OpenAlex ID | https://openalex.org/A5033519199 |
| ORCID iD | https://orcid.org/0000-0002-6754-5633 |
| Works | 1,156 |

## Researcher papers

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)
- [Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung](https://scholariq.org/papers/results-from-the-phase-iii-randomized-trial-of-onartuzumab-plus-erlotinib-versus/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Princess Alexandra Hospital](https://scholariq.org/institutions/princess-alexandra-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.